NDC 61434-053-00 - Abrilada
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 61434-053
- Requested NDC
- 61434-053-00
- Package NDCs from labels
- 61434-053-00
- Manufacturer
- Catalent Indiana, LLC
- Effective date
- 2023-07-06
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Abrilada - Catalent Indiana, LLC | Catalent Indiana, LLC | 2023-07-06 | HUMAN PRESCRIPTION DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| AMJEVITA | ADALIMUMAB-ATTO | Amgen USA Inc. | b7178e36-6787-45ab-8fee-be59bc6a4aa4 | 2026-07-13 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| AMJEVITA | ADALIMUMAB-ATTO | Amgen, Inc | 9c44bd5b-4464-40a4-8933-8680950f00f2 | 2026-06-25 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| AMJEVITA | ADALIMUMAB-ATTO | Nuvaila Limited | d7862491-2634-4402-b001-dcc1abf8dd58 | 2026-06-25 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| HADLIMA | ADALIMUMAB-BWWD | A-S Medication Solutions | c361dd60-c88d-4f3c-b98c-79687bbc3450 | 2026-05-14 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| Adalimumab | ADALIMUMAB-ADAZ | Sandoz Inc | 3468792f-63ef-4916-8ed1-8214f327d9dd | 2025-10-21 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| HYRIMOZ | ADALIMUMAB-ADAZ | Cordavis Limited | 3e303a4a-980b-4f2a-9d03-786928758637 | 2025-10-17 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| HYRIMOZ | ADALIMUMAB-ADAZ | Sandoz Inc | 1ac7d061-3380-468c-b077-c05f8dfbc829 | 2025-10-17 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| Adalimumab-bwwd | ADALIMUMAB-BWWD | Cordavis Limited | c24655e5-796e-4127-b716-92f08d649c83 | 2025-10-17 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| YUSIMRY | ADALIMUMAB-AQVH | Coherus BioSciences Inc | cd0e7af2-7704-49ce-bde9-f645294b6788 | 2025-05-16 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| HADLIMA | ADALIMUMAB-BWWD | A-S Medication Solutions | 7345f276-102e-4175-b7ef-ff1706b05472 | 2023-10-23 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| HADLIMA | ADALIMUMAB-BWWD | A-S Medication Solutions | ef25af7e-6267-409a-8d68-de51eb48812a | 2023-10-02 | Boxed warning, Warnings, Adverse reactions | FYS6T7F842 |
| 16c2517e-623a-4c5c-a714-017c71f65d5d | f2ee682a-8ea6-4068-bdbe-8a9e7d1a2514 | 2023-09-26 | f2ee682a-8ea6-4068-bdbe-8a9e7d1a2514 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.